linjc16/ctgov huggingface dataset:
Relation of Blood-boron Levels With Body Mass Index

Study Overview
=================
Brief Summary
-----------------
According to our experimental experiences w hypothesized that blood boron levels may be corralated to body mass index.

Detailed Description
-----------------
In the results of our experimental study on mices we revealed that low dose oral boric acid intake cause seriously body mas reducing. Although blood and urine analyses support high glucose, lipid and middle protein catabolisms, but the mechanism was unclear. There are some diseases according to blood elementary deficiencies, like hypothyroidi in hypoiyodinemia, hiperparathyroidi in hypocalcemia, etc. We hypothesised that hypoboronemia may be corralated to body mass index level.

Official Title
-----------------
Phase 1 Study of Blood Boron Levels According to Body Mas Index

Conditions
-----------------
Obesity

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: body mas index levels in over 19 peoples Exclusion Criteria: known chronic, morbid and malign diseases

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 45 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| normal<br>body mass index: 19-24 | |
| overweight<br>body mass index: 25-29 | |
| obesity<br>body mass index: 30-40 | |
| modbid obes<br>body mass index: over 40 | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| blood boron level | blood boron levels will be measured cantitatively | 6 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| body mass index | body mass index levels will be evaluated with blood boron levels | 6 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
obesity, etiology, pathogenesis, treatment
Ectopic Pregnancy Biomarkers

Study Overview
=================
Brief Summary
-----------------
In an attempt to simplify the diagnosis of ectopic pregnancy, the researchers will investigate the presence of specific molecular markers of ectopic pregnancy. The quantification of these (and other proteins) will be performed using the Ciphergen Protein Chip system where serum is sampled with a high-throughput system. The patterns of these peaks will be compared for those with a diagnosis of ectopic pregnancy and normal pregnancy. Later goals of the research will be to identify the actual proteins that correspond to the peaks which discriminate between the two clinical entitles. The goal is to identify a unique protein pattern or protein peak to distinguish a normal intrauterine pregnancy from that of an ectopic implanted gestation.

Official Title
-----------------
Serum Bank for Assessment of Markers of Ectopic Pregnancy

Conditions
-----------------
Ectopic Pregnancy

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Reproductive-aged women Currently pregnant based on serum human chorionic gonadotropin level Present for care for pregnancy due to vaginal bleeding and/or pelvic cramping Final diagnosis of one of the following: Live intrauterine pregnancy through 14 weeks, diagnosed by ultrasound demonstrating fetal heart motion Diagnosed ectopic pregnancy Ultrasound confirmation of a nonviable gestation (less 14 weeks) such as an anembryonic gestation or a fetal demise Exclusion Criteria: None
Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
ectopic pregnancy
Seroprevalence of SARS-CoV-2 in Unselected Surgical Patients: an Unicentric, Regional Study

Study Overview
=================
Brief Summary
-----------------
The investigator analyzed the data of the patients admitted to the surgical department during the period 1St September - 10Th December 2020 to estimate the seroprevalence of SARS-CoV-2 infection in the setting of a non-dedicated COVID-19 hospital and in a mild CoV-2 incidence area and to evaluate the difference of seroprevalence between Spring and Fall seasons in a cohort of patients undergoing surgery.

Official Title
-----------------
Seroprevalence of SARS-CoV-2 in Unselected Surgical Patients: an Update From an Unicentric, Regional Study

Conditions
-----------------
SARS-CoV Infection, Seroprevalence, Covid19

Intervention / Treatment
-----------------
* Diagnostic Test: Antibodies testing


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patient admitted to our unit who had performed SARS-COV-2 serologic test Exclusion Criteria: age < 18

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Diagnostic Test: Antibodies testing|Serologic test for both SARS-COV-2 IgG and IgM|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| SARS-COV-2 seroprevalence | SARS-COV-2 IgG and IgM seroprevalence between spring and fall period | 1St September - 10Th December 2020 |
Treatment of the lOw IGF-1 Syndrome aSsociated With Chronic Heart fAilure: A Randomized, Placebo-Controlled, Double-Blind Study.

Study Overview
=================
Brief Summary
-----------------
The objective of the study is to determine whether treatment of the low IGF-1 syndrome in patients with CHF is able to modify some functional parameters, recognized as valid surrogate end-points of CHF progression.

Official Title
-----------------
Phase 2 Study of Growth Hormone Administration in Patients With Chronic Heart Failure and Low IGF-1 Levels

Conditions
-----------------
Chronic Heart Failure

Intervention / Treatment
-----------------
* Drug: Growth Hormone
* Other: Placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patients of either sex affected by CHF NYHA class II-III, secondary to ischemic or idiopathic dilated cardiomyopathy age range 30-80 years stable medications for at least two months prior to randomization, including ACE inhibitors or AT1 antagonists and beta-blockers (unless untolerated). LV ejection fraction 40% or less Peak VO2 consumption during a CPET ≤ 16 ml/kg/min. LV end-diastolic dimension 55 mm or more low IGF-1 levels and a satisfactory response to an IGF-1 generation test informed consent Exclusion Criteria: haemodynamic clinically significant primary valvular disease or significant congenital heart disease acute pericarditis/myocarditis inability to perform a bicycle exercise test Poorly controlled diabetes mellitus (HbA1c >8.5) active proliferative or severe non-proliferative diabetic retinopathy active and/or history of malignancy evidence of progression or recurrence of an underlying intracranial tumor unstable angina or recent myocardial infarction (less than 5 months) severe liver disease serum creatinine levels >2.5 mg/dl Inability to cooperate or administer the study drug Patients participating in any other clinical study, within 30 days prior to screening visit and/or during this particular study period

Ages Eligible for Study
-----------------
Minimum Age: 30 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: GH replacement therapy<br> | Drug: Growth Hormone<br>* growth hormone administration<br>|
| Placebo Comparator: Placebo<br> | Other: Placebo<br>* standard placebo<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| increase of peak VO2 consumption by at least 2.5 ml/kg/min during maximal physical exercise test. |  | 9 months |
BIIB014 Effects on the Pharmacokinetics (PK) of Rosiglitazone, Warfarin, and Midazolam

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to understand whether BIIB014 has potential to affect how certain drugs are broken down by the body.

Official Title
-----------------
A Randomized, Double-Blind, Placebo-Controlled, Crossover Study to Assess the Effect of BIIB014 on the Pharmacokinetics of Rosiglitazone, Warfarin, and Midazolam in Healthy Volunteers

Conditions
-----------------
Healthy

Intervention / Treatment
-----------------
* Drug: BIIB014
* Drug: Placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Healthy male or female subjects Between the ages of 18 and 45, inclusive. Must have a body mass index (BMI) between 19 kg/m2 and 30 kg/m2, inclusive Exclusion Criteria: Clinically significant abnormalities (as determined by the Investigator) Other unspecified reason that would make the subject unsuitable for enrollment (as determined by the Investigator)

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 45 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Other
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Rosiglitazone 8mg PO<br>Cohort 1 | Drug: BIIB014<br>* BIIB014 100mg PO Cohort 1 - 8d Cohort 2 - 14d<br>Drug: Placebo<br>* Matched placebo to BIIB014 Cohort 1 - 8d Cohort 2 - 14d<br>|
| Experimental: Midazolam 2mg PO, Warfarin 25mg PO<br>Cohort 2 | Drug: BIIB014<br>* BIIB014 100mg PO Cohort 1 - 8d Cohort 2 - 14d<br>Drug: Placebo<br>* Matched placebo to BIIB014 Cohort 1 - 8d Cohort 2 - 14d<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Pharmacokinetic profile of rosiglitazone (Cohort 1), midazolam & metabolites and s-warfarin (Cohort 2) during steady state exposure to BIIB014 or placebo |  | 24 hours (Cohort 1); 144 hours (Cohort 2) | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Adverse Events |  | Duration of subject participation | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Healthy Volunteer
Impact of Cataract Surgery on Keratoplasty Graft Survival

Study Overview
=================
Brief Summary
-----------------
The follow up time after keratoplasty now routinely exceeds multiple decades. It is common for keratoplasty patients to also undergo cataract surgery at a later date in their lives. Keratoplasties and cataract surgery both result in local inflammation. This may influence the density of endothelial cells, and on average there is a loss of 10% in endothelial cells within 3 months of the cataract surgery. Yet, a sufficient density of endothelial cells is required to maintain graft transparency. It may be therefore difficult to strike a balance between loss of visual acuity due to the cataract of to the loss of graft transparency over the long term. The investigators aim to compare graft survival in patients with clear crystalline lens with and without cataract surgery.

Official Title
-----------------
Impact of Cataract Surgery on Keratoplasty Graft Survival

Conditions
-----------------
Cataract, Fuchs' Endothelial Dystrophy, Keratoconus

Intervention / Treatment
-----------------
* Procedure: Cataract surgery


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: All patients undergoing keratoplasty Between january 1983 and december 2012 Age 40 and older at the time of surgery Exclusion Criteria: Cataract surgery prior to the keratoplasty Systemic inflammatory disease Previous history of uveitis

Ages Eligible for Study
-----------------
Minimum Age: 40 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Keratoplasty with cataract surgery<br>Patients who underwent keratoplasty who also underwent a cataract surgery during follow up. | Procedure: Cataract surgery<br> <br> |
| Keratoplasty without cataract surgery<br>Patients who underwent keratoplasty who never underwent cataract surgery. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Corneal transplant graft survival |  | 10 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Corneal endothelial cell density |  | 10 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Corneal Transplantation, Graft Survival
To Investigate the Event Related Potentials (ERPs) of Patients With Brain Lesions

Study Overview
=================
Brief Summary
-----------------
Event-related potentials (ERPs）has the advantage of excellent temporal resolution on measuring real-time neural activities that reflect to higher level cognitive processes. A research project related to lesion studies in which patients with cognitive function impairment and communication disorder will be recruited as participants to examine their impairment as well as residual abilities by using ERPs. Hopefully, expected findings will provide further analysis based on the patterns of neural activities revealed by both patients and normal controls should be able to provide important evidence toward building the cross-linguistic theory. The findings also have applications on diagnostic and evaluation for patients with brain lesions for clinical application with communication disorder.

Conditions
-----------------
Brain Lesions

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patients with new brain lesions confirmed by imaging study Exclusion Criteria: patients with recurrent brain lesions
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| patients with brain lesions<br> | |
| young normal controls<br> | |
| old normal controls<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
patients with brain lesions
Unattended In-home Sleep Recording: A Pilot Study

Study Overview
=================
Brief Summary
-----------------
Laboratory studies have found that insufficient sleep duration and impaired sleep quality are associated with disease risk, including obesity, diabetes and heart disease. The limitation to the laboratory studies is that they are conducted in artificial environments that do not reflect real-world behavior. Although the epidemiologic studies do reflect habitual behavior, the vast majority of them rely on self-reported measures of sleep, which are only moderately correlated with objective measures of sleep.. The next logical step in the examination of sleep's role in cardiometabolic health is to conduct objective, detailed measures of sleep in people's homes. This project is a pilot study that will develop ideal methodologies for recording sleep in the home environment. Because there is currently is a gap between laboratory models of sleep loss and real world conditions, the ultimate goal of this research is to expand our work on sleep and cardiometabolic health outside of the laboratory. Given the strong evidence for a link between impaired and insufficient sleep and increased disease risk, it is critical that we understand how people sleep in their daily lives and what factors can impact sleep. This project will record sleep in people's homes using ambulatory polysomnography recordings and wrist actigraphy.

Official Title
-----------------
Unattended In-home Sleep Recording: A Pilot Study

Conditions
-----------------
Sleep

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Must have had a polysomnography recording at the University of Chicago. Exclusion Criteria: None.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Sleep Architecture | Sleep architecture (stages) from polysomnography | once |
Comparation of Radial and Focused Extracorporeal Shock Waves in Calcaneal Spur: A Randomised Sham-controlled Trial

Study Overview
=================
Brief Summary
-----------------
To date, focused and radial types of ESWT have been effectively used in calcaneal spur. However, studies directly addressing a comparison between radial and focused types of ESWT in calcaneal spur have not been done. Therefore, this study aims to evaluate comparative effects of radial and focused ESWT options on calcaneal spur.

Official Title
-----------------
Comparative Effects of Radial and Focused Extracorporeal Shock Wave Therapies on Calcaneal Spur: A Randomised Sham-controlled Trial

Conditions
-----------------
Calcaneal Spur

Intervention / Treatment
-----------------
* Device: Focus extracorporeal shock wave therapy
* Device: Radial extracorporeal shock wave therapy
* Device: Sham extracorporeal shock wave therapy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Clinical and radiological diagnosis of plantar calcaneal spur be aged ≥18 at the time of diagnosis be give informed consent Exclusion Criteria: have not completed the assessment process. foot deformity psychological disease

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Focus extracorporeal shock wave therapy<br> | Device: Focus extracorporeal shock wave therapy<br>* Focus extracorporeal shock wave therapy, device: Electronica, Pagani, Italy<br>|
| Active Comparator: Radial extracorporeal shock wave therapy<br> | Device: Radial extracorporeal shock wave therapy<br>* Radial extracorporeal shock wave therapy, device: Electronica, Pagani, Italy<br>|
| Sham Comparator: Sham extracorporeal shock wave therapy<br> | Device: Sham extracorporeal shock wave therapy<br>* Sham extracorporeal shock wave therapy, device: Electronica, Pagani, Italy<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Visual Analogue Scale | pain evaluation, higher scores mean a worse outcome. | 1 min. | 
| American Orthopedic Foot and Ankle Score | higher scores mean a better outcome. | 5 min. | 
| FOOT FUNCTION INDEX | higher scores mean a worse outcome. | 7 min. |
Assessing Foot Injuries in Infantry Recruits Wearing Different Boots

Study Overview
=================
Brief Summary
-----------------
One hundred infantry recruits will be randomly assigned to two groups. Injuries will be monitored.

Detailed Description
-----------------
One hundred infantry recruits will be randomly assigned to receive experimental infantry boots (DEFINITE-REGULATOR) or standard issued boots (modified Belleville 390 TROP). Overuse injuries and foot injuries will be monitored over a period of 14 weeks. The intervention group will wear experimental infantry boots and the controls will wear standard issue boots.

Official Title
-----------------
Assessing Foot Injuries in Infantry Recruits Wearing Different Boots, a Prospective Randomized Study

Conditions
-----------------
Blister, Abrasion, Stress Fracture, Ankle Sprain, Patellofemoral Pain Syndrome, Back Pain

Intervention / Treatment
-----------------
* Device: Experimental infantry boot - DEFINITE-REGULATOR
* Device: Control infantry boot


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Infantry recruits on selected base Exclusion Criteria: None

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 25 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: DEFINITE-REGULATOR<br>Training with DEFINITE-REGULATOR experiment infantry boots manufactured by Brill Industries, Rishon LeZion, Israel | Device: Experimental infantry boot - DEFINITE-REGULATOR<br>* Training: infantry basic training in the experimental boots<br>|
| Active Comparator: modified Belleville 390 TROP<br>Standard issue infantry boot | Device: Control infantry boot<br>* Training: infantry basic training in the control boots<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of recruits with at least one injury related to the boots | Injuries assessed: Blister, Abrasion, Stress Fracture, Ankle Sprain, Patellofemoral Pain Syndrome, Back Pain | 14 weeks |